Last updated: April 23, 2026
Who supplies allopurinol active pharmaceutical ingredient (API)?
Allopurinol API supply is split between (1) chemical manufacturers producing API and (2) contract manufacturers that prepare marketed dosage forms under label/market licenses. The API supply base for allopurinol is concentrated in established chemical and generic pharma supply chains, with availability tied to global filings for “allopurinol” drug substance manufacturing sites.
Because “allopurinol suppliers” depends on whether you mean API, finished dosage forms (tablets), or both, the supplier set below is organized by market-facing procurement categories.
Who are the main finished-dosage suppliers for allopurinol tablets?
In most jurisdictions, allopurinol is commercialized as generic tablets across multiple strengths (commonly 100 mg and 300 mg). Finished-dosage supply is therefore provided by generic manufacturers operating branded and store-label products.
Common allopurinol tablet strengths and procurement implications
- 100 mg tablets: typically supplied as generic formulations under multiple marketing authorizations
- 300 mg tablets: commonly used for maintenance dosing and larger pack sizes
How finished-dosage suppliers are typically structured
- Market authorization holder / brand labeler: controls the dossier and specification release
- Manufacturing site: produces tablets under GMP; may be different from the labeler
- Packaging site: repack and secondary packaging often run separately
This structure affects vendor qualification and audit scope for purchasers.
What supplier “types” appear in allopurinol sourcing bids?
Allopurinol sourcing usually uses one or more of these supplier types:
- API manufacturer (drug substance)
Supplies allopurinol API with CoA, DMF support (where applicable), and GMP documentation.
- Finished-dose manufacturer (drug product)
Supplies tablets packaged for market distribution with release testing.
- Wholesaler / distributor
Supplies finished product through distribution channels, typically for local tendering.
Which regions dominate allopurinol supply?
Allopurinol supply tends to be concentrated in regions with high generic manufacturing density, including:
- India (strong generic API and finished-dose ecosystem)
- China (large-scale chemical and API capacity)
- EU/UK (role for finished-dose GMP manufacturing and label holding)
- US (site-level finished-dose and label holding for generic drug products)
How to map suppliers for procurement: a practical framework
Purchasers generally qualify suppliers using a chain-of-evidence approach:
- Regulatory link: confirm the manufacturer and site on the marketing authorization and product label
- GMP readiness: verify GMP certificates for the manufacturing site
- Quality package: CoA format, release specifications, impurity profile reporting
- Supply reliability: batch frequency and market coverage by strength
This is the baseline method used for RFP screening for established oral generics.
What procurement documentation is expected for allopurinol supply?
For both API and finished-dose procurement, vendors typically provide:
- GMP certificate for the manufacturing site
- CoA with assay and impurity results per batch
- Specification sheet (release and in-process)
- Stability data for the drug product (finished-dose only)
- Drug master file (DMF) or equivalent dossier reference for API (where used in the buyer’s region)
What are key technical constraints when sourcing allopurinol?
Allopurinol is a well-established small molecule with:
- Multiple generic tablet presentations
- A stable chemistry profile
- Quality driven mainly by impurity control, polymorph form (where relevant for specific formulations), and consistent dissolution performance for tablets
Procurement risk is usually linked to:
- batch-to-batch consistency and impurity control at the API level
- tablet dissolution and content uniformity at the finished-dose level
Supplier shortlist by category (what to request in sourcing bids)
Below is the procurement-facing shortlist structure used in real-world tenders for a low-complexity, high-volume oral generic like allopurinol.
API category (request from chemical suppliers)
- API manufacturer of record and site
- DMF or dossier reference (if your regulatory process relies on it)
- Release assay and impurity specs for each relevant grade
- Typical lead time and batch sizes
Finished-dose category (request from tablet manufacturers)
- Finished-dose manufacturer of record and site
- CoA and dissolution acceptance method
- Strengths and pack formats offered (100 mg and 300 mg)
- Traceability and recall readiness plan
Distributor category (request from wholesalers)
- Product source (NDC/MA number or local equivalent)
- Lot traceability and temperature control process (if required by local rules)
- Availability by strength and pack size
What supplier evidence matters most in compliance audits?
For allopurinol, auditors usually focus on:
- manufacturing site GMP compliance
- validations supporting tablet performance (content uniformity, dissolution)
- change control history for formulation, manufacturing process, and packaging
- impurity trend monitoring from API through final release
Which regulatory databases are used to identify allopurinol manufacturing sites?
Procurement teams typically cross-check:
- FDA Orange Book (US marketing status, for drug product and application holders)
- EMA and national databases (EU marketing authorization data)
- USDMF / EMA registers (for API dossiers and sites, where available through access)
These sources identify the “who” behind marketing authorizations and manufacturing sites.
Key Takeaways
- Allopurinol supply is a generic manufacturing ecosystem: procurement must separate API suppliers from finished-dose manufacturers.
- Finished-dose procurement typically involves multiple labelers and manufacturing sites depending on strength (commonly 100 mg and 300 mg).
- Vendor qualification should center on manufacturing site GMP evidence, batch CoA/impurity reporting, and tablet dissolution/content-uniformity release controls.
- Regulatory databases are the fastest path to map true manufacturing sites behind the marketed products.
FAQs
1) Is allopurinol sourced more often as API or as finished tablets?
It is commonly sourced as finished tablets for direct procurement; API sourcing is used when the buyer runs local manufacturing or tolling.
2) What allopurinol tablet strengths are most commonly supplied?
The most commonly referenced commercial strengths are 100 mg and 300 mg tablets.
3) What should a purchaser require in vendor qualification for allopurinol?
Purchasers typically require GMP certificates for the site, CoAs, specifications, and for tablet products dissolution and content uniformity release controls.
4) Where do teams look to identify the manufacturer behind a marketed allopurinol product?
Teams typically use regulatory listing sources such as FDA Orange Book (US) and EMA or national authorization databases (EU).
5) What quality risks show up most in allopurinol supply chains?
The largest operational risks typically come from impurity control at the API level and tablet performance consistency (dissolution/content uniformity) at the finished-dose level.
References
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] European Medicines Agency. Human medicines: Marketing authorisation. EMA. https://www.ema.europa.eu/en/medicines
[3] European Medicines Agency. EU Dossier and product information registers (where applicable). EMA. https://www.ema.europa.eu/en/registration-and-information/eu-dossier-search
